Effectiveness outcome
SECONDARY
A key secondary objective is to assess the effect of mPATH™-CRC on screening rates (effectiveness), comparing 8 months of data prior to implementation to 8 months of data following implementation. The detectable difference (difference in screening rates pre vs post) depends on the sample size, power, ICC, and cluster sample size CV. We assume a screening rate in the pre-implementation group of 15%, as observed in the control group in the previous randomized-controlled efficacy study [Detectable difference in screening rates pre vs. post as a function of the power and the ICC (22 clinics)To evaluate whether the effect of mPATH™-CRC on screening rates differs by implementation strategy, the period (pre vs post) by strategy (“high touch” vs “low touch”) interaction can be evaluated. Based on the control group from the previous randomized-controlled efficacy study, we anticipate a screening rate of 15% for “low touch” and pre- implementation. An increase in the screening rate from 15% to 25% from pre to post, corresponds to an odds ratio (OR) of 3. Similarly, assuming a screening rate in the “low touch” group of 15%, and a screening rate of 25% in the “high touch” group, also corresponds to an OR of 3. By design, we anticipate half of the patients being in the “high touch” group and half in the post period, and that strategy and period are independent. Based on these assumptions, Table Detectable interaction odds ratio as a function of the ICC (22 clinics)